

PRESS RELEASE

Cipla strengthens its presence in Kenya

Nairobi, 25th September 2014: Cipla Limited, a global pharmaceutical company which uses cutting edge technology and innovation to meet the healthcare needs of patients, today announced that the company aims to build a strong presence in Kenya. In line with its global strategy, Cipla continues to retain ownership of its marketing authorisations and trademarks for its products in Kenya and will continue to invest further in developing the Kenya market. The company has recently introduced its own office in Kenya. The products will be brought to Kenyan patients in partnership with Surgipharm Limited.

Over the years, Cipla has been working with various partners in Kenya and has been supplying a basket of products across various key therapies – anti-HIV, anti-malarial, anti-asthma, gastroenterology, anti-infectives, cardiovascular and oncology among others.

Mr. Subhanu Saxena, MD & Global CEO, Cipla Limited said, “Our strong presence in Kenyan market will ensure that patients are able to receive affordable, high-quality medicines. Cipla is a company which provides one quality standard globally with manufacturing approvals from all the key international regulatory authorities.”

About Cipla Limited:

Cipla Limited is a global healthcare company which uses technology and innovation to meet the healthcare needs of patients in various therapy areas. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across almost 170 countries. Cipla’s turnover in 2013-14 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla’s research and development focuses on developing innovative products and drug delivery systems and has given India and the world many ‘firsts’ for instance Triomune. In a tightly regulated environment, the company’s manufacturing facilities have approvals from all the main regulators including US FDA, UK MHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.